We work with clients large and small around the globe, from major pharmaceutical companies to small and mid-size biotechnology and medical device companies.
We tailor our services to accommodate the specific needs of our clients and their clinical trials, from single-site, investigator-initiated studies to large multi-center Phase III pivotal trials.
We are responsive, a value that pivots on listening and understanding the specific goals, concerns, and timeline requirements of our clients throughout each project.
Our preferred approach is “right-to-left”—starting from the desired pharmaceutical label or relevant clinical endpoints and working back to the beginning. This approach enables us to ensure the most efficient and cost-effective trial design and greatest probability of success.
We have flexibility and capacity—with a biostatistics staff comprising more than 30 professionals—to respond rapidly as protocols change or are amended, whether we are working with a small company on a project basis or supplementing the in-house staff of a large multinational pharmaceutical company.
We empower our Project Managers to “speak for Axio,” with the full resources of our company at their disposal and the authority to commit those resources to meet client timelines.
Our biostatisticians apply deep experience in multiple disciplines and are active in the professional and academic community—attending FDA and ASA meetings, preparing abstracts and manuscripts, participating in courses and webinars, and presenting at scientific sessions.
We work hard to help our clients keep their trials running efficiently.
